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Characterization and understanding of gut microbiota has recently increased representing a wide research ﬁeld, especially in
autoimmune diseases. Gut microbiota is the major source of microbes which might exert beneﬁcial as well as pathogenic eﬀects
on human health. Intestinal microbiome’s role as mediator of inﬂammation has only recently emerged. Microbiota has been
observed to diﬀer in subjects with early rheumatoid arthritis compared to controls, and this ﬁnding has commanded this study
as a possible autoimmune process. Studies with intestinal microbiota have shown that rheumatoid arthritis is characterized by
an expansion and/or decrease of bacterial groups as compared to controls. In this review, we present evidence linking intestinal
dysbiosis with the autoimmune mechanisms involved in the development of rheumatoid arthritis.
1. Introduction
Rheumatoid arthritis (RA) is a systemic, inﬂammatory, and
chronic disease characterized by a persistent immune
response that leads to inﬂammation and destruction of joints.
The etiopathogenic mechanisms involved are complex and
include an interaction between the innate and acquired
immune response, involving antigen-presenting cells
(APCs), autoreactive T cell formation, and production of
autoantibodies directed against their own cellular structures,
like rheumatoid factor (RF) and anticitrullinated protein
antibodies (ACPAs). These antibodies are often present in
the blood, long before any sign of joints’ inﬂammation,
suggesting that the triggering of autoimmunity might occur
at diﬀerent sites to the joints, for example, the gastrointestinal
tract or airway [1]. Epidemiological studies suggest rheuma-
toid arthritis as the result of complex interactions between
genes, environmental and hormonal factors, and the immune
system [2, 3].
There is a genetic susceptibility to rheumatoid arthritis by
a tendency to familial aggregation, a concordance between
monozygotic twins and an association with some histo-
compatibility antigens [4, 5]. Heritability estimates have
suggested a 60–70% genetic risk factors, responsible for
developing rheumatoid arthritis [6]. Candidate gene or
genome-wide association studies have identiﬁed diﬀerent
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risk loci associated with rheumatoid arthritis etiology. Cur-
rently, in this disease, about 100 described genes are associ-
ated with susceptibility, protection, severity, activity, and
treatment response [6]. Human leukocyte antigen (HLA)
polymorphisms are the most important genetic risk factors.
HLA are an important part of the immune system triggering
T cells of the immune system to produce antibodies. Associ-
ations of RA with HLA-DRB1 alleles have been observed in
all racial and ethnic populations [7, 8]. The shared epitope
(SE), a 5-amino acid sequence motif in positions 70–74 of
the HLA–DRβ chain, is the most signiﬁcant genetic risk
factor for rheumatoid arthritis [9]. Some SE alleles, such
as HLA-DRB1∗0401, appear to confer a higher risk than
others; moreover, the presence of two SE alleles and in
particular HLA-DRB1∗0401/∗0404 confers a high risk to
develop the disease and has also an inﬂuence on disease
severity [10]. SE alleles are associated with ACPA-positive
rheumatoid arthritis, but only relatively weakly with
ACPA-negative rheumatoid arthritis [8]. SE alleles might
contribute to the genetic predisposition to rheumatoid
arthritis causing an immune dysregulation (controlling
both speciﬁcity and amount of ACPA production) or a
premature immunosenescence [10].
In genetically disease-susceptible individuals, subsequent
environmental triggers might induce rheumatoid arthritis
development. The bacterial and viral components are an
attractive source of antigens capable of inducing rheumatoid
arthritis and, therefore, have been the most investigated as
potential causal agents [3]. However, there is no conclusive
evidence to date of a causal relationship of a microorganism
with rheumatoid arthritis.
In recent years, characterization and understanding of
this gut microbiota has increased and constitutes a wide
research ﬁeld, especially in autoimmune diseases. The gut
microbiota is the major source of microbes that may exert
beneﬁcial as well as pathogenic eﬀects on human health
[11]. Encouraged by studies that show alterations in intes-
tinal microbiota composition in autoimmune diseases, such
as rheumatoid arthritis, the interest of studying microorgan-
isms as potential candidates in the development of autoim-
munity has been renewed [11–14].
Findings supporting the idea that the onset of autoimmu-
nity may be related to gastrointestinal tract are as follows: (1)
microbial composition in subjects with early rheumatoid
arthritis diﬀers to controls, with a reduction of certain bacte-
ria belonging to the family Biﬁdobacterium and Bacteroides
[15, 16], and a marked increase of species belonging to the
genus Prevotella [17]. (2) In murine models, the parenteral
injection of cell wall fragments from various intestinal bacte-
ria is arthritogenic [17] and in this model, arthritis is not
developed when bred in germ-free conditions; otherwise, it
is presented when intestinal bacterial species are introduced
[18]. (3) Diet has been shown to inﬂuence inﬂammatory
activity levels [19]. (4) Some drugs used to treat rheumatoid
arthritis have antimicrobial eﬀects (chloroquine, sulfasala-
zine, minocycline, and roxithromycin) [20–23]. (5) Altered
microbiome was partially restored to normality in patients
showing clinical improvement after prescribing disease-
modifying antirheumatic drugs [5, 18]. So, diﬀerences in
composition of intestinal microbiota and in the immune
system function could determine which patients develop
the disease.
A great eﬀort is currently being made to study subjects
with rheumatoid arthritis in preclinical phase. Awareness of
the mechanisms that initiate the autoimmune process, as well
as the ones involved in the transition from pre- to clinical
phase, might guide to intervention strategies which allow its
prevention or treatment in very early stages of the disease.
Some publications suggest that rheumatoid arthritis early
treatment leads to better long-term outcomes and perhaps
to increased rates of drug-free remission [24]. Prevention
concept is an emerging research ﬁeld in rheumatology area,
in which modiﬁcations of the microbiota could be a new
way of modulating the disease.
2. Immunopathogenesis of
Rheumatoid Arthritis
Understanding the complex molecular processes that play
a role in the pathogenesis of rheumatoid arthritis is still
a challenge. Susceptible individuals under genetic and
environmental factors with loss of immunological toler-
ance to self-antigens trigger the autoimmune phenomena
and the autoantibody formation [25]. This lack of immuno-
logical tolerance represents the ﬁrst step towards autoimmu-
nity. Immune system dysregulation is characterized by the
presence of autoantibodies and autoreactive T cells. The
inappropriate generation of autoreactive B cells is the most
obvious alteration of the immune system in these patients;
they are detected long before the disease appears. The most
important are RF and ACPAs that recognize diﬀerent pro-
teins in the citrullinated form [26]. Together with increased
autoantibody production, proinﬂammatory cytokines’ level
is elevated in the joint synovium of patients with rheumatoid
arthritis. The joints of patients with RA are complicated
tissues where innate and adaptive immune cells along with
joint resident cells, like synoviocytes and chondrocytes, are
involved [27].
Multiple cell types have been identiﬁed to contribute to
the pathogenic context in rheumatoid arthritis. In rheuma-
toid synovium, dendritic cells are found mainly in lympho-
cytic aggregates and peripheral vessels, suggesting that they
come from peripheral blood. MHC alleles are expressed by
APCs that processed extracellular peptides to CD4+ T cells,
driving the secretion of proinﬂammatory cytokines that
stimulate B cells to produce antibodies [25]. Patients with
the disease present a defective function of circulating regu-
latory T cells (Treg) and an increase in T helper 17 (Th17)
cells in plasma and synovial ﬂuid [28]. Macrophage-derived
and dendritic cell-derived transforming growth factor β
and interleukin-1β, 6, 21, and 23 provide a milieu that sup-
ports Th17 diﬀerentiation and suppresses diﬀerentiation of
regulatory T cells, thus shifting T cell homeostasis towards
inﬂammation [29].
Posttranslational modiﬁcations (PTMs) are critical for
the function and antigenicity of proteins. The three PTMs
primarily involved in rheumatoid arthritis are glycosylation,
carbamylation, and citrullination [25]. Citrullination results
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from the conversion of arginine onto citrulline by the enzyme
peptidyl arginine deiminases (PAD), and this is the major
crucial posttranscriptional modiﬁcation associated to self-
antigen recognition in rheumatoid arthritis [25]. Citrulline
may alter protein structure and generate new epitopes asso-
ciated with the production of ACPAs. ACPAs present in
rheumatoid arthritis patients show diﬀering ﬁne speciﬁc-
ities and cross-reactivity degrees with various citrullinated
and/orposttranslationallymodiﬁedpeptides/proteins, includ-
ingﬁbrinogen, ﬁbronectin, α-enolase, collagen type II, and
histones [30].
Table 1 summarizes the relevant aspects in the evolution
of this disease. Preclinical rheumatoid arthritis comprises the
period in which the autoimmunity is detectable until the
beginning of the inﬂammation and/or injury of clinically
apparent tissue, genetic and environmental risk factors
interact, probably sequentially, to initiate and propagate the
development of autoimmunity, ﬁnally resulting in detectable
tissue inﬂammation and lesion [24, 31]. If any other risk
factor is involved in the onset and/or spread of the disease,
it is still unknown.
ACPAs’ response might be important to transition from
preclinical phase to clinical expression of rheumatoid arthri-
tis. ACPAs’ repertoire analysis prior to diagnosis in patients
with rheumatoid arthritis revealed that this immune
response starts in a very restricted manner and expands to
several months or even years (epitope spreading, from
one initially recognized epitope towards reactivity to many
diﬀerent epitopes) before the diagnosis of rheumatoid arthri-
tis [10, 24, 32, 33]. Epitope spreading towards more citrulli-
nated ones is compatible with the possibility that a single
antigen (but not always the same) is responsible for starting
up the immune response [16, 32]. Sokolove et al. [33]
reported that earlier identiﬁed autoantibodies were targeted
against various ligands of the innate immune response
including citrullinated histones, ﬁbrinogen, and biglycan.
Over time, the ACPAs’ titers and epitope diversity of ACPAs
increase, especially before arthritis onset. ACPAs could be
isotypes IgG, IgA, or IgM with an altered glycosylation status
that confers enhanced Fc-receptor and citrullinated antigen
binding [34]. ACPAs themselves can be pathogenic by acti-
vating either macrophages or osteoclasts via immune com-
plex formation and Fc-receptor engagement or probably by
binding membrane citrullinated vimentin, thus promoting
bone loss [34].
Since the original description of antibodies as citrulli-
nated antigens in a subpopulation of rheumatoid arthritis
patients, it has become clear that citrullinated epitopes of a
large number of autoantigens as well as antigens derived
from microorganisms can be recognized by highly speciﬁc
antibodies for rheumatoid arthritis [30]. Alterations at
speciﬁc mucosal sites suggest that microbial factors might
aﬀect mucosal immune response, also playing an impor-
tant role in early pathogenesis of rheumatoid arthritis
[35]. Alterations in compositional diversity and abundance
levels of microbiota, that is, dysbiosis, can trigger several
types of autoimmune and inﬂammatory diseases through
the imbalance of T cell subpopulations, such as Th1, Th2,
Th17, and Treg cells [27].
Dysbiosis in one or more mucosal sites leads to immune
alterations and breaks in self-tolerance to citrullinated auto-
antigens [35]. Mucosal body surfaces such as respiratory
and gastrointestinal tract carry out complex tasks as they
must (1) remain tolerant against innocuous environmental,
nutritional, and microbial antigens to ensure organ function
and (2) set eﬃcient immune responses against invading
Table 1: Natural history of rheumatoid arthritis.
Phase of initiation of the disease
(interaction between genetic-hormonal-environmental factors)
Preclinical RA Clinical RA
Genetic and epigenetic
factors
Hormonal factors
Environmental
factors
Immunological changes Immunological changes
Shared epitope, PTPN22,
STAT4, CTLA4, TRAF1,
PADI4, FCRL3, TNFIP3
DNA methylation
Dysregulated histone
marks
Relationship man :
woman 4 : 1
Arthritis is improved
in the pregnancy but
relapse in the postpartum
Microbiota oral,
pulmonary and
intestinal
Smoking
Silica dust
Obesity
Diet
Inadequate response to peptides
Expansion of autoreactive
T cells and B cells
Expansion of antibody isotype
usage and class switching
Changes in soluble cytokine
and chemokine networks
Altered Th17 cells and Th17/
regulatory T cell ratios
Upregulation of signalling
molecules
Immune-mediated
tissue inﬂammation
Alterations of autoantibodies,
such as glycosylation
Cellular expansion
Clinical manifestations Clinical manifestations
Presence of autoantibodies
(RF, ACPAs)
Nonspeciﬁc symptoms
Arthritis
Bone erosions
Systemic symptoms
Forms of intervention
Suspension of smoking
Avoid exposure to silica
Healthy diet
Maintaining an adequate weight
Modiﬁcations of the microbiota?
In research, the early use
of rituximab or abatacept
Modiﬁcations of the microbiota?
Anti-inﬂammatory
Biological and nonbiological
disease-modifying drugs
Glucocorticoids
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pathogens [36]. Lung and gut tissues contain immunological
cells able to initiate an immune response; an attractive possi-
bility is that the triggering of T cell-mediated immunity to
citrullinated autoantigens can occur in the mucosae after
presentation of neoantigens by APCs [1, 31]. In mucosal
site, possible roles for citrullinated microbial antigens and
molecular mimicry, Toll-like receptor (TLR) signals, and
other innate immune activators and danger signals might
exist [35]. Mucosa-associated bacterial ﬂora and smoking
or environmental particles (silica dust) act on immune
cells (neutrophils, dendritic cells, and macrophages) as
pathogen-associated molecular patterns and damage them,
leading to inﬂammation onset, circulating cytokines, and
chemokine increase along with autoantigen production.
The citrullinated antigens are processed and presented by
the APCs to the T cells, which are activated and in turn
activate the B cell, leading to the production of autoanti-
bodies [31]. Autoantigens in rheumatoid arthritis are not
tissue- and organ-speciﬁc but comprise a large collection of
posttranslational modiﬁed proteins [31]. Smoking and other
stimuli might initiate citrullination by PAD activation, for-
mation of lymphoid structures that could enhance antigen
presentation, and T and B cell production [31]. Potential
mechanisms by which cigarette smoke (CS) promotes
rheumatoid arthritis include release of intracellular proteins
from reactive oxidative substances activated or injured cells,
augmentation of autoreactive B cell function, and alteration
of (a) many cell signaling pathways involved in cellular
activation, (b) cigarette smoke-impaired antigen-presenting
cells, (c) regulatory T cell functions, and (d) T cell activation
by antigens found in cigarette smoke [37].
3. Microbiota and the Immune System
Microbial exposures in gastrointestinal and respiratory tracts
are key determinants of the overall immune tone at these
mucosal barriers and represent a leading target for future
intervention strategies [36]. Gut is an entryway for various
environmental antigens in the form of food or infectious
agents. Intestinal microbiota is a factor inﬂuencing metabolic
homeostasis and the immune system [5]; it is a site of
remarkable interaction between microorganisms and human
body. Microorganisms establish a symbiotic relationship
with epithelial and lymphoid tissue [12, 25]. Intestinal bacte-
ria synthesize and change a variety of compounds that aﬀect
physiology and immunity. However, not all host-microbiota
interactions promote health, particularly species of resident
bacteria seem to activate the immune system resulting in
inﬂammatory diseases [38, 39]. A diverse and balanced
microbiota is necessary to develop an appropriate immune
response [40].
Beneﬁts provided by gut microbiota to the host rely on
intricate interactions with host cells [41]. Studies using
germ-free and gnotobiotic animals, colonized with deﬁned
bacteria, provided direct evidence about microbiota’s crucial
role in development and maintenance of the host immune
system [41] and preservation of its functions such as matura-
tion of intestinal lymphoid tissue, secretion of immunoglob-
ulin A, and the production of important antimicrobial
peptides [42]. In axenic mice, scarce growth of lymphoid
tissue and alterations in T cells and subpopulations of B
lymphocyte development were observed; in some cases, these
mice did not develop diseases presented in ordinary subjects,
probably due to defects in the adaptive immune system in the
absence of the microbiota, rather than to the absence of
microorganisms per se. Conserved molecular patterns, either
expressed on the surface of symbiotic bacteria or secreted in
the intestine, may interact with pattern recognition receptors
(PRRs), which are expressed on or within epithelial and
lymphoid cells to initiate transduction and transcription of
signals from a set of molecules that mediate host defense or
metabolic activities within the gut [40].
Intestinal commensal microbiota have been shown to
modulate T cell and Treg responses that are required for
eﬀective host defense against pathogens while circumvent-
ing autoimmune responses and other immunopathologic
consequences [43]. As the ﬁrst line defense of host against
pathogens, innate immune responses rely on a family of
receptors known as PRRs including TLRs and nucleotide-
binding oligomerization domain-like receptors (NLRs).
TLRs are key innate immune receptors to perceive
pathogen-associated molecular patterns (PAMPs), which
are speciﬁc pathogenic “molecular signature.” Subsequent
to sensing microbial PAMPs, TLRs enable the initiation of
inﬂammatory responses and eventually eliminate the patho-
genic invaders [43]. Components of gram-positive and
gram-negative bacteria interact with TLRs to mediate both
innate and adaptive immunity, as well as other cellular func-
tions of the mucosal barrier [40]. Epithelial cells have TLRs
on their cell membrane, which allow the recognition of
PAMPs and the activation of MyD88 coupling protein-
mediated signaling that ends with the induction of an inﬂam-
matory response and the production of proinﬂammatory
cytokines such as tumor necrosis factor-alpha (TNF-α),
interleukin-6, or interleukin-1β. The innate immune
response cells of the lamina propria constantly examine the
contents of the intestinal lumen for foreign antigens and con-
stitute another defense mechanism [28]. Because commensal
bacteria diﬀer in their ability to stimulate receptors for innate
immunity (TLRs and NLRs), the pattern of released chemical
mediators varies signiﬁcantly by determining proinﬂamma-
tory or anti-inﬂammatory responses. Lipopolysaccharide of
gram-negative bacteria binds to TLR-4, whereas peptidogly-
can and other components of the cell wall of gram-positive
bacteria signal via the TLR-2 pathway generating an immune
response [11]. Gram-positive anaerobic bacteria contain a
greater amount of polysaccharides and peptidoglycans that
may act as antigenic stimuli.
After interaction with an antigen, dendritic cells play an
important role in the diﬀerentiation of immature CD4+ lym-
phocytes into Th1, Th17, or Th2 cells. The diﬀerentiation of
the T helper cells seems to be deeply inﬂuenced by the intes-
tinal microbiota [11, 16, 42]. Dendritic cells act as APCs by
displaying charged peptides in their MHC class II molecules.
Presentation of these molecules to B cells or to T cell recep-
tors sensitizes these cells to initiate an adaptive immune
response [28]. In rheumatoid arthritis, dendritic cells could
participate in maintenance of inﬂammatory process by
4 Journal of Immunology Research
regulating antigenic presentation, and the presentation of the
antigen or the arthritogenic antigens would then be abnor-
mally prolonged, which might favor the perpetuation of
inﬂammation. Macrophages and dendritic cells continuously
detect intestinal lumen antigens and evaluate the presence of
deleterious antigens. Antigens are presented by MHC II mol-
ecules and interact with B cells or T cell receptors to induce
adaptive immune responses. Depending on the microbial
antigen, a speciﬁc cytosine medium is then generated to
inﬂuence a speciﬁc type of T helper cell diﬀerentiation. While
type 1 T helper (Th1) cells develop in response to intracellu-
lar pathogens and produce interferon, both type 2 T helper
(Th2) cells and Th17 cells are stimulated by extracellular
microorganisms. Th17 cells contribute to the defense against
extracellular pathogens by the production of IL-17 and IL-22,
which induce the change of immunoglobulin class in B lym-
phocytes and the production of Reg3g by epithelial cells,
respectively [14]. The immune response generated by eﬀector
T cells is regulated by the subpopulation known as regulatory
Treg cells. Intestinal Treg cells play an important role in
maintaining immune tolerance to dietary antigens and gut
microbiota [44]. Treg cells retain tolerance to self-antigens
and eliminate autoimmunity. CD4+CD25+ Treg cells are
suppressive cells, which express the transcription factor
Foxp3, and are indispensable for maintenance of immune
self-tolerance and homeostasis by suppressing aberrant or
excessive immune response. Lactobacillus and Biﬁdobacter-
ium infantis exert an anti-inﬂammatory eﬀect through the
induction of CD4+CD25+FoxP3+ Treg cells [11]. Bacteroides
fragilis polysaccharide A acts as an immunomodulator
and stimulates CD4+ Treg cells through an interleukin-
2-dependent mechanism to produce IL-10 [11].
Taking into account the fact that dendritic cells are
fundamental in generating immune response, it has been
hypothesized that commensal bacteria inﬂuence the function
and diﬀerentiation of dendritic cells, thus modulating
immune response [11, 23]. Thus, intestinal dysbiosis can
induce arthritis by inﬂuencing the diﬀerentiation of T cell
subgroups. It also inﬂuences the expression degree of Toll-
like receptors of antigen-presenting cells and may contribute
to an unbalance in the Th17/Treg cell ratio. With the devel-
opment of Th17 cells, activating local inﬂammatory cascades
with tissue damage and in predisposed individuals, this local
immune response can lead to systemic autoimmunity with
self-reactive Th17 cells.
The microbiota are the most prominent inﬂuence from
the environment on the diﬀerentiation of Th17 cells.
Recently, much attention has been paid to segmented ﬁla-
mentous bacteria (SFB) because of its ability to induce the
production and activation of Th17 cells in the intestine, with
the secretion of interleukin-17 [23, 27]. SFB comprise a
group of Clostridia-related gram-positive bacteria that
adhere closely to Peyer’s plaques in the small intestine and
can stimulate the immune response by inducing IgA secre-
tion and activating B cells. These bacteria are necessary for
the development of autoimmunity in the murine K/BxN
arthritis model [45], and the use of antibiotics prevents
the advance of arthritis [13, 30, 31]. Studies in murine
models revealed that induction of TFH and Th17 cells
precedes the onset of arthritis, indicating a role for both
types of cells. Monocolonization with SFB enhances the
production of autoantibodies and accelerates the progression
of disease through the generation of Th17 cells although a
microbiota-induced TFH cell-dependent process can also
precipitate disease [44]. Teng et al. [46] demonstrated that
SFB trigger autoimmune arthritis by inducing diﬀerentiation
and migration of gut T follicular helper cells (TFH) to sys-
temic lymphoid sites, leading to increased autoantibody pro-
duction and arthritis exacerbation. In contrast, Block et al.
[45, 47] conﬁrmed a role for gut microbiota in the diﬀerenti-
ation of TFH cells and germinal center formation. Depletion
of gut microbiota in mice by antibiotics reduced the number
of TFH cells and antibody production levels. They concluded
that intestinal microbiota regulates the development of
arthritis through TFH independently of Th17 cells.
4. Dysbiosis in Rheumatoid Arthritis
Importance of gut microbiome in autoimmunity related to
rheumatoid arthritis has been implicated in both mouse
models and human disease. Alterations of microbiota are
related to risk and severity of the disease. Three sites have
been associated particularly with it, mainly the lungs, oral
mucosa, and gastrointestinal tract. However, the site(s) of
initial immune response triggering remains to be veriﬁed.
Whereas precise mechanisms that enhance risk are not fully
understood for each, it is likely that local tissue stress leads
to posttranslational modiﬁcation of peptides with subsequent
antibody formation serving as a common mechanism [48].
Airway abnormalities and lung tissue citrullination are
found in both rheumatoid arthritis patients and individuals
at risk. This suggests the lung as a possible site of autoimmu-
nity generation [49]. Evidence of an early role of the adaptive
immunity and immune activation in the lungs of these
patients comes from a proteomic study where two shared
citrullinated vimentin peptides have been described in bron-
chial tissue form early rheumatoid arthritis patients and
synovial tissue from patients with established disease, oﬀer-
ing some clues on an immune process initiated in the lungs
[25]. The pulmonary mucosa as an autoimmune process
origin is based on the following observations: ACPAs are
presented in the sputum of ACPA-positive patients without
arthritis; there are microscopic and macroscopic changes in
the lungs with early rheumatoid arthritis and untreated
ACPA-positive patients; pulmonary alterations have been
demonstrated in high-resolution computed tomography in
subjects without the disease but with ACPA-positive; pulmo-
nary biopsy samples from patients with ACPA positive with
established AR suggest that ACPAs are produced locally.
However, the precise molecular mechanisms that could
be responsible for the triggering of immunity in the lung
mucosa are relatively unexplored. It is known that lung
exposure to harmful agents, including smoke, may induce
increased expression and activation of PAD [1]. It has
been hypothesized that the citrullinated proteins may
become an autoantigen and thereby trigger an immune
system response in people with genetic predisposition for
rheumatoid arthritis.
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Smoking and periodontitis promote protein citrullina-
tion and ACPA production [50]. Attention in the gums is
based on periodontal disease, more frequent in subjects with
rheumatoid arthritis or correlated with its activity. It has been
speculated that periodontal pathogens drive systemic inﬂam-
mation or disseminate to aﬀected tissue. Indeed, increased
speciﬁc IgG to periodontal pathogens, including Prevotella
intermedia and Porphyromonas gingivalis, has been reported
in RA [51]. The presence of P. intermedia and P. gingivalis in
the subgingival dental plaque, as well as synovial ﬂuid, sup-
ports a role of microbiota in initiating or maintaining chronic
inﬂammation [52]. Cross-sectional studies have revealed cor-
relations between RA and higher titers of serum antibodies
against proposed periodontal pathogens such as P. gingivalis,
Prevotella melaninogenica, and Tannerella forsythia [53].
Oral inoculation with P. gingivalis and Prevotella nigrescens
aggravated the severity of arthritis in an experimental mouse
model by directing the immune pathway towards production
of IL-17 and generation of a Th17 response [54]. The eﬀects
of the two bacteria diverged in that P. nigrescens, in contrast
to P. gingivalis, suppressed the joint-protective type 2 cyto-
kines, including IL-4. P. gingivalis expresses an enzyme with
amino deiminase activity that converts C-terminal arginine
to citrulline, similar to the one involved in the etiology of
rheumatoid arthritis. Citrullination of bacterial and human
proteins by PAD can expose hidden epitopes leading to
tolerance loss in genetically susceptible individuals. It is
believed that the resulting immune response together with
endogenous citrullination produces ACPAs [4]. The fact that
smoking is strongly linked to the presence of periodontitis
and P. gingivalis infection provides circumstantial evidence
in favor of this hypothesis. However, recent epidemiological
data have not demonstrated a clear relationship between
periodontitis and rheumatoid arthritis [1].
Recently, gut microbiota has been proposed as an indis-
pensable environmental factor in the progression of rheuma-
toid arthritis [5, 18, 27, 55–57]. Bennike et al. [43] identiﬁed
21 citrullinated peptides in the colonic tissue from both rheu-
matoid arthritis patients and controls, which have been pre-
viously found in lung tissue and synovial ﬂuid from RA
patients. Three citrullinated proteins (citrullinated vimentin,
ﬁbrinogen-alpha, and actin) are known targets for ACPAs,
supporting that colon mucosa could be a potential break
site for immune tolerance towards citrullinated epitopes.
Citrullinated vimentin was found with increased abun-
dance in the colonic tissue of these patients compared to
the controls, which could indicate that initial rheumatoid
arthritis triggering is not limited just to a speciﬁc location
in the body but can take place in many other locations [43].
Therefore, this study supports the hypothesis that colon
mucosa could serve as a break site for immune tolerance
to citrullinated proteins, triggering ACPA production in
patients with impaired immune system.
5. Gut Microbiota in Rheumatoid Arthritis
Potential role of intestinal microbiota in etiopathogenesis of
rheumatoid arthritis is supported by studies in animal
models, by research on intestinal microbioma, and indirectly,
by the eﬀect of diet and probiotics in the degree of inﬂamma-
tory activity. Pathophysiologic mechanisms by which gut
microbiota is associated with arthritis is probably multifacto-
rial; proposed mechanisms include activation of antigen-
presenting cells through an eﬀect on TLRs or NLRs, ability
to produce citrullinization of peptides by enzymatic action,
antigenic mimicry, alterations in permeability of intestinal
mucosal, control of host immune system (triggering T cell
diﬀerentiation), and increase of T helper type 17-mediated
mucosal inﬂammation.
Despite the existence of animal models, it is well known
that there is no animal model that represents rheumatoid
arthritis entirety [58]. However, murine arthritis models have
shown to induce erosive polyarthritis by intraperitoneal
injection of cell wall fragments of Streptococcus pyogenes,
Lactobacillus casei, and Eubacterium aerofaciens [59–61].
The arthritogenicity of bacterial structures depends on bacte-
rial species, and remarkably, even bacteria from the normal
intestinal microbiota cause experimental arthritis in animals
[17]. Gnotobiotic mice do not develop arthritis, and intro-
duction of SFB is enough to reintegrate Th17 cells from the
lamina propria, a greater production of autoantibodies and
a rapid development of destructive arthritis [62]. Antibiotic
treatment prevents and suppresses a phenotype similar to
rheumatoid arthritis in several murine models [4, 18, 28],
and in genetically susceptible mice, dysbiosis increases
sensitivity to arthritis through activation of autoreactive
T cells in the gut [63].
Intestinal microbiota’s role in pathogenesis of arthritis
was demonstrated by the induction/exacerbation of arthritis
in experimental murine models [55, 64–66]. Studies with
gnotobiotic mice have shown that disruptions in the intesti-
nal microbiota could induce production of proinﬂammatory
cytokines, interleukin-17, and increased levels of Th17 cells,
even in extraintestinal tissues [11]. Th17 cells then migrate
into the peripheral lymphoid tissue and secrete IL-17, which
in turn, acts directly on B cells and induces systemic B cell
diﬀerentiation and antibody production [67]. This ultimately
can lead to development of autoimmune disease via molecu-
lar pattern recognition from gut microbiota [67]. The IL-1
receptor antagonist (IL-1Ra) knockout mice, which sponta-
neously develop autoimmune T cell-mediated arthritis, do
not develop disease when raised in a germ-free environment.
However, colonization with commuter Lactobacillus biﬁdus
produces a rapid onset of the disease, severity, and incidence
comparable to the arthritis observed in mice. L. biﬁdus trig-
gers arthritis in this model by promoting an imbalance in
Treg–Th17 cell homeostasis and mediated through Toll-like
receptor signaling (TLR2-TLR4) [28, 65]. Liu et al. [64]
found that the genus Lactobacillus was signiﬁcantly more
abundant in collagen-induced arthritis- (CIA-) susceptible
mice prior to arthritis onset than in CIA-resistant mice.
Notably, germ-free mice conventionalized with the microbi-
ota from CIA-susceptible mice showed a higher frequency of
arthritis induction than those conventionalized with the
microbiota from CIA-resistant mice. Monocolonization of
germ-free K/BxN mice with SFB was suﬃcient to drive pro-
duction of autoantibodies and pathogenic Th17 cells as well
as to trigger arthritis [66]. Systemic deﬁciencies of germ-
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free animals reﬂect a loss of Th17 cells from the intestinal
lamina propria. Introduction of a single species of resident
intestinal ﬁlamentous bacteria restored the Th17 cell com-
partment into the lamina propria; autoantibodies production
and arthritis occurred rapidly. Thus, a single commensal
microbe, through its ability to promote a speciﬁc subpopula-
tion of T helper cells, can lead to an autoimmune disease
[66]. These results provide the evidence that commensal
bacteria can drive autoimmune arthritis by inducing a Th17
response in the intestine. Therefore, composition of gut
microbiota plays a pivotal role in the balance between inﬂam-
matory Th cells and suppressive Treg cells to maintain
immune tolerance under healthy conditions [27].
Interaction between host genetic factors such as MHC
and intestinal microbiota and its impact on development of
rheumatoid arthritis is diﬃcult to study in humans because
of the high variability of genetic factors and diet [11].
Research conducted by Gomez et al. [68] provided the ﬁrst
demonstration that HLA genes and intestinal environment
interact to aﬀect the susceptibility of arthritis. This study
showed diﬀerences in fecal microbiome of rheumatoid
arthritis-susceptible HLA-DRB1∗0401 transgenic mice
compared to DRB1∗0402 mice resistant to development of
rheumatoid arthritis. Speciﬁcally, DRB1∗0401 female mice
had signiﬁcantly diﬀerent microbial to DRB1∗0402 females,
and this resulted in an increase in intestinal permeability
and transcripts of Th17 type cytokines in DRB1∗0401 mice.
The analysis showed that the intestinal ﬂora of arthritis-
susceptible mice had a greater amount of Clostridium sp.
bacteria, while those of DRB1∗0402 resistant to arthritis were
enriched by the families Porphyromonadaceae and Biﬁdobac-
teriaceae [68]. The latter organism has been associated with
the anti-inﬂammatory response in the intestinal mucosal
immune systems through the suppression of T cell prolif-
eration and the production of proinﬂammatory cytokines
and by inhibition of nuclear factor kB. The results show
a diﬀerence in intestinal microbial composition between
the two strains, suggesting that MHC genes may be directly
or indirectly involved in determining the intestinal micro-
bial composition and that interactions between bowel
commensals [13, 18]. In addition, they demonstrated that
dysbiosis is not enough since it requires a genetic suscepti-
bility of the host, due to an induction inability in inﬂamma-
tory response in wild animals, even with proarthritogenic
intestinal ﬂora [13, 28].
Several studies attempting to link gut mucosal and joint
inﬂammation have been followed during the past decades.
Eerola et al. [69] reported that fecal proﬁle of bacterial cell
fatty acids was signiﬁcantly diﬀerent in subjects with rheu-
matoid arthritis, mainly by anaerobic bacteria compared to
controls. They support the idea that rheumatoid arthritis
represents a state of chronic inﬂammation that could be
motivated or aggravated by pathogenic bacteria overgrowth
or by a lack of common immunomodulating bacteria
[5, 16, 18, 57, 70]. Vaahtovuo et al. [16] also described dif-
ferences in fecal diversity in individuals with rheumatoid
arthritis compared to those with ﬁbromyalgia, character-
ized by lower bundi-bacteria, Bacteroides-Porphyromonas-
Prevotella, subgroup Bacteroides fragilis, and the group
Eubacterium rectale-Clostridium coccoides in subjects with
rheumatoid arthritis [6]. On the other hand, Newkirk et al.
[71] identiﬁed diﬀerences in the types of E. coli pathogen
colonization among subjects with rheumatoid arthritis,
RF-positive patients were more commonly colonized with
E. coli, phylogenetic group D, whereas RF-negative patients
were more commonly colonized with E. coli, phylogenetic
group B2, and these individuals also had lower joint scores
and inﬂammatory markers yet higher IgA anti-E. coli
antibody responses.
The observation that gut microbiota diﬀers in subjects
with early rheumatoid arthritis compared to controls has
renewed the interest in studying intestinal microbiota as a
possible site of origin of the autoimmune proces; studies that
evaluate the intestinal microbiota show that rheumatoid
arthritis is characterized by an expansion and/or decrease
of bacterial groups as compared to controls [5, 18, 55–57].
High-throughput sequencing of stool samples in 5 studies
of RA patients showed gut dysbiosis [5, 18, 55, 57, 63], and
2 study reported overexpansion of Prevotella sp. in patients
with early RA, particularly P. copri (Table 2). Diﬀerences
between the bacteria reported in the studies may be inﬂu-
enced by the time course of the disease (i.e., early versus
established), subjects included in the control groups
(healthy or ﬁrst degree relatives), the treatment received,
and the geographical location, since the studies do not
show the same pattern.
Toivanen et al. [57] compared fecal microbiota from 25
patients with early RA to the microbiota of patients with
noninﬂammatory pain using oligonucleotide probe against
16S RNA. Patients with early RA had signiﬁcantly fewer bac-
teria belonging to the gender Bacteroides sp., Prevotella sp.,
and Porphyromonas sp. In other study, Scher et al. [18]
reported that individuals with early RA were more likely to
harbor Prevotella copri compared to controls. In addition,
they demonstrated that oral administration of P. copri
increased local inﬂammatory response in a colitis murine
model. Therefore, P. copriwould alter intestinal permeability.
Such increase might lead to bacteria penetration and/or its
components throughout the body; this is one of the proposed
mechanisms that link dysbiosis with the pathogenesis of
arthritis. Interestingly, the relative abundance of P. copri
showed a negative correlation with the presence of shared
epitope, suggesting that the composition of the human
intestinal microbiome could also be partially dependent
on the host genome and suggesting a dysbiosis before
the appearance of the clinical phenotype.
In line with these results, Maeda et al. [63] observed that
P. copri was in abundance within gut microbiota in Japanese
patients with early RA who had not received drug treatment.
They identiﬁed that P. copri per se had a high capacity to
induce Th17 cell-related cytokines, such as IL-6 and IL-23.
Increased Prevotella sp. abundance is associated with aug-
mented T helper type 17-mediated mucosal inﬂammation,
which is in accordance with the marked capacity of Prevotella
sp. in driving Th17 immune responses in vitro [51]. In other
study, Pianta et al. [72] identiﬁed that subgroups of rheuma-
toid arthritis patients have diﬀerential IgG or IgA immune
reactivity with P. copri. In both new onset rheumatoid
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arthritis patients and chronic ones, a subgroup had IgA anti-
body responses to either Pc-p27 or the whole organism,
which correlated with Th17 cytokine responses and frequent
ACPAs. The second subgroup had IgG P. copri antibodies,
which were associated with Prevotella DNA in synovial ﬂuid,
P. copri-speciﬁc Th1 responses, and less frequent ACPAs.
Patients with RA had IgA, IgG, or no speciﬁc antibodies,
indicating that diﬀerent immune responses to P. copri can
develop within the individual patient, which in turn may
have implications for disease risk and outcomes.
Molecular mimicry, due to its sequence similarities
between foreign and self-peptide, is one such mechanism
known to result in cross-activation of pathogen-derived
autoreactive T or B cells. These T and B cells can cross-
Table 2: Summary of studies that have evaluated the inﬂuence of gut ﬂora on the etiopathogenesis of RA.
Author (year
of publication)
Design Subjects included Method employed Results in the RA group versus the controls
Shinebaum
et al. [70]
Case-
control
25 patients with RA
compared with controls
Estimation of bacterial
counts in fecal culture
Signiﬁcantly higher carriage rate of
Clostridium perfringens in the RA population
than controls (88% versus 48%, p < 0 01).
Coliform counts also tended to be higher
Eerola
et al. [69]
Case-
control
74 treatment-naive
early RA and 91 non-RA
controls
Gas-liquid chromatography
of bacterial CFAs
Variation in CFA proﬁle of RA as
compared to controls likely caused by
anaerobic bacteria
Vaahtovuo
et al. [16]
Case-
control
50 individuals with RA
and 50 individuals with
ﬁbromyalgia
Flow cytometry, 16S
rRNA hybridization,
and DNA-staining
The RA patients had signiﬁcantly less biﬁdobacteria
and bacteria of the Bacteroides-Porphyromonas-
Prevotella group, Bacteroides fragilis subgroup, and
Eubacterium rectale-Clostridium coccoides group
Toivanen
et al. [57]
Case-
control
25 treatment-naive
individuals with early
RA patients and
23 control patients
suﬀering from
noninﬂammatory pain
16S ribosomal DNA
Patients with early RA had signiﬁcantly less
bacteria belonging to the Bacteroides, Prevotella,
and Porphyromonas genera than the controls
(4.7% versus 9.5%, p < 0 01). The number of
bacteria belonging to the Bacteroides-Prevotella-
Porphyromonas group was, on average, in RA
patients only half that of the controls
Scher
et al. [18]
Cross-
sectional
44 treatment-naive
individuals with RA,
26 treated RA,
16 patients with psoriatic
arthritis, and 28 healthy
controls
16S ribosomal DNA
Increases in Prevotella copri (75% versus 21.4%)
abundance and decrease in Bacteroides
Liu
et al. [56]
Case-
control
15 individuals with
early RA and 15 healthy
controls
Quantitative
real-time PCR
Fecal microbiota of RA patients contained
signiﬁcantly more Lactobacillus
(10.62± 1.72 copies/g) than the control group
(8.93± 1.60 copies/g)
Zhang
et al. [5]
Cohort
77 treatment-naive
individuals with RA and
80 unrelated healthy
controls; 17 treatment-naive
individuals with RA paired
with 17 healthy relatives;
and 21 samples from
DMARD-treated
individuals with RA
Metagenomic shotgun
sequencing and a
metagenome-wide
association study
The RA gut was enriched in gram-positive
bacteria and depleted of gram-negative
bacteria, including some Proteobacteria and
gram-negative Firmicutes of the Veillonellaceae
family. The RA-enriched MLGs formed a large
cluster including Clostridium asparagiforme,
Gordonibacter pamelaeae, Eggerthella lenta, and
Lachnospiraceae bacterium. There was a trend
towards increased abundance of P. copri as a
function of RA duration in the ﬁrst year
Maeda
et al. [63]
Cross-
sectional
25 treatment-naive
individuals with early
RA patients and
23 healthy controls
16S rRNA-based
deep sequencing
A subpopulation of early RA patients harbored
intestinal microbiota dominated by Prevotella copri
Chen
et al. [55]
Case-
control
40 Subjects with RA
with treatment
16S ribosomal DNA
Increased number of reads from the phylum
Actinobacteria in the RA group (0.45 versus 0.04%)
32 controls (15 relatives
of 1 degree with AR and
17 healthy subjects)
Decrease in Faecalibacterium and expansion of
Collinsella aerofaciens and Eggerthella lenta
MLGs: metagenomic linkage groups.
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react with host epitopes, thus leading to autoimmunity [67].
In a recently work, Pianta et al. [73] described two proteins
derived from common types of gut bacteria that could evoke
the immune responses in RA patients. N-Acetyl-glucos-
amine-6-sulfatase (GNS) and ﬁlamin A (FLNA) were identi-
ﬁed as autoantigens that produce responses from both T and
B cells, in over 50% of RA patients, but not in healthy con-
trols or patients with other rheumatic diseases. The HLA-
DR-presented GNS peptide has marked sequence homology
with epitopes from sulfatase proteins of the Prevotella sp.
and Parabacteroides sp., whereas the HLA-DR-presented
FLNA peptide has homology with epitopes from proteins of
the Prevotella sp. and Butyricimonas sp., another gut com-
mensal. T cell responses to the corresponding microbial
and self-peptides were strongly correlated. These study pro-
vides evidence that T cell epitopes of a related order of gut
microbes, particularly Prevotella sp., may cross-react with
self-epitopes of highly expressed proteins in joints, especially
in patients with SE alleles.
Moreover, Prevotella sp. may not be the only genus par-
ticipating in inﬂammatory disease. Zhang et al. [5] used
metagenomic shotgun sequencing technology to analyze
fecal, dental, and salivary samples from a large cohort of
RA patients as well as from healthy controls. Analysis of dif-
ferentially represented metagenomic linkage groups revealed
signiﬁcant microbiome diﬀerences between RA patients and
healthy controls, not only in fecal but also in salivary and
dental samples. They demonstrated that gram-positive bacte-
ria enriched microbiota versus few gram-negative bacteria
and, furthermore, that dysbiosis was associated with inﬂam-
mation markers and clinical rheumatoid arthritis activity.
Besides, they also detected alterations in redox environment
and transport and metabolism of iron, sulfur, and zinc in
the microbiota of RA patients, indicating that the altered
microbiome could play an important role in the pathogenesis
of RA. Noteworthy, altered microbiome was partially
restored to normal (microbiome of healthy controls) in
patients who showed clinical improvement after prescribing
disease-modifying antirheumatic drugs. Remarkably, P. copri
in RA-aﬀected individuals showed a trend of increasing
relative abundance in the ﬁrst year, consistent with its
reported expansion in early RA. Many Prevotella species
were enriched in the saliva of RA subjects compared with
controls. One notable exception was Prevotella intermedia,
which was enriched in the control group. However, in
dental plaque samples, there was a very diﬀerent picture
and most Prevotella sp. were present at higher proportions
in healthy subjects.
Chen et al. [55] reported that bacteria belonging to the
phylum Actinobacteria play a signiﬁcant role in the patho-
genesis of rheumatoid arthritis, Collinsella sp. and Eggerthella
sp. predicted its presence, and dysbiosis in the intestinal
microbiome is partially restored after treatment with
disease-modifying antirheumatic drugs, similar to results
reported in the previous study. The potential association of
P. copri as previously reported with new onset untreated
RA and DR4 was not observed in this cohort of RA patients
(in contrast to previous studies, all the patients in the present
study were currently on a treatment regimen). They showed
that the decreased gut microbial diversity of RA patients is
associated with disease duration after adjusting for various
drugs used for treatment. Collinsella sp. may contribute to
the development of rheumatoid arthritis through molecular
mimicry as it presents sequences shared with DRB1∗0401.
The role of the RA-associated bacteria Collinsella sp. was
conﬁrmed using a human epithelial cell line and a humanized
mouse model of arthritis. Collinsella sp. enhanced disease
severity in a humanized mouse model. One mechanism by
which Collinsella contributes to disease pathogenesis is by
increasing gut permeability as observed by the lower expres-
sion of tight junction proteins. Additionally, Collinsella
inﬂuences the epithelial production of IL-17A [55].
Although studies in subjects with rheumatoid arthritis
show a correlation of Prevotella sp. in its pathogenesis, other
studies suggest that it may be considered a beneﬁcial bacterial
species rather than pathogenic [74, 75]. Culture collections
now include approximately 40 diﬀerent Prevotella species,
most of them oral isolates, and three of which are found in
the gut (P. copri is generally the more abundant). The vastly
diﬀerent genome gene repertoires of strains within and
between Prevotella sp. and across hosts probably underlie
some of the diﬀerences observed in responses at the genus
level to diet and health conditions across individuals [75].
A recent comprehensive study comparing several bacterial
species suggests that membership of a speciﬁc phylum does
not predict immunological properties, underlining the
importance of characterizing properties at species level.
Marietta et al. [76] evaluated the ability of 2 species of Prevo-
tella sp. for arthritis prevention and treatment in HLA-DQ8
mice. It was shown that the ability to modulate the immune
response diﬀered between the Prevotella strains. Treatment
with P. histicola suppressed arthritis development by mod-
ulating the immune response (regulation of dendritic cells
and generation of Treg cells), resulting in suppression of
Th17 responses and reduction of inﬂammatory cytokines
(IL-2, IL-17, and tumor necrosis factor). In contrast,
administration of P. melaninogenica showed no signiﬁcant
change in cytokine levels, either preventing arthritis
development. The ability of P. histicola to modulate was
validated using a DBA/1 mouse model, demonstrating that
mice treated with P. histicola developed milder arthritis
compared to controls. It is clear that a single strain of Prevo-
tella sp. can act in what has been interpreted as a beneﬁcial
or detrimental manner, depending on the context. This
may explain why Prevotella sp. is abundant in healthy
microbiota and suggests that only certain strains may
exhibit pathogenic properties.
In new onset RA patients, Prevotella abundance in the gut
was at the expense of Bacteroides fragilis, an organism that is
important for Treg function [18, 72]. In fact, high levels of
P. copri and similar species are related to low levels of bene-
ﬁcial microbes, which are believed to suppress the immune
system and metabolize vitamins in forms absorbed into the
bloodstream [17]. When discussing possible mechanisms by
which diet could inﬂuence rheumatoid arthritis, eﬀects of
intestinal ﬂora should be considered [77–79]. A diet rich
in protein and animal fat is associated with the presence
of Bacteroides sp. while a diet rich in carbohydrates is
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associated with the presence of Prevotella sp. [80]. Studies
have shown that Mediterranean or vegan diet reduces
inﬂammatory activity, increases physical function, and
improves vitality [19]. However, some other studies ﬁnd
beneﬁts without achieving a signiﬁcant improvement in
composite indices to measure disease activity [81, 82].
Nevertheless, in these studies, it has not been determined
whether a rheumatoid arthritis improvement was actually
due to a change in intestinal ﬂora composition.
Probiotics are living organisms that can confer a health
beneﬁt to the host. Probiotics mainly exert their beneﬁcial
eﬀects through the following three methods: antimicrobial
eﬀects, enhancement of mucosal barrier integrity, and
immune modulation [83]. Studies [84–86] assessing the rela-
tionship between probiotic supplementation with the level of
RA activity have not shown conclusive results (Table 3).
Improvements in probiotic interventions have not been evi-
dent enough to demonstrate the eﬀectiveness of treating RA
patients, due to the limited studies. Better-designed research
needs to be conducted in order to identify the best species
that relieve RA and optimize the intake method and doses
of the probiotics [83].
Finally, evidence that intestinal microbiota motivates
arthritis development comes from murine experimental
models. In humans, this association is based in diﬀerences
between microbiome within comparison groups, which do
not necessarily represent its causality. Results in humans
suggest dysbiosis as a signiﬁcative etiologic agent promoting
rheumatoid arthritis progression or, even more, that inﬂam-
mation caused by some microorganisms like P. copri, may
probably contribute to arthritis maintenance. In order to
predict intestinal microbiota’s role in pathogenesis of rheu-
matoid arthritis, an accurate comprehension related to this
species potential, its ecology and interaction with other
microbes and/or hosts would still be necessary. Furthermore,
although gut mucosal got probably the highest potential for
host-microbe interaction, all mucosae have resident microbi-
ota and react dynamically to its presence with an immune
modulation. Gram-negative bacteria could cause infections
at any part of the body; among the most common types are
oral, dental, pleuropulmonar, intra-abdominal, genital
mucosal, skin, and soft tissues. In other words, it does not
mean that all subjects with rheumatoid arthritis must have
dysbiosis in a single site.
6. Microbiota as a Possible Mechanism for
Rheumatoid Arthritis Prevention
Current research projects are focused on prevention with
biological drugs that inhibit antibody formation or activate
T cells [87]. Recent ﬁndings showed intestinal dysbiosis as a
major advance in our understanding of rheumatoid arthritis.
Nevertheless, there is no study demonstrating the antigen
or antigens that trigger the autoimmune process. Logical
indications point mucosal dysbiosis as an attractive site
for elucidating autoimmunity pathways, particularly the
mechanisms that induce loss of immune tolerance and
speciﬁc mechanisms by which a person evolves from a
preclinical to a clinical disease.
Gut microbiota has been shown to play role in rheuma-
toid arthritis although the mechanism of this association
remains obscure. Understanding these mechanisms is crucial
for a better treatment eﬃcacy and personalized patient man-
agement [67]. Plasticity of microbiome may allow a speciﬁc
or systematic manipulation of a certain intestinal microbiota
associated with host diseases [88], speculating that, in the
future, this manipulation could change therapeutic strategies
in subjects with rheumatoid arthritis.
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